WallStSmart

IQVIA Holdings Inc (IQV)vsSotera Health Co (SHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 1302% more annual revenue ($16.31B vs $1.16B). IQV leads profitability with a 8.3% profit margin vs 6.7%. IQV appears more attractively valued with a PEG of 0.97. IQV earns a higher WallStSmart Score of 72/100 (B).

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33

SHC

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.5Value: 4.7Quality: 5.8
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued
SHCSignificantly Overvalued (-37.4%)

Margin of Safety

-37.4%

Fair Value

$12.64

Current Price

$13.70

$1.06 premium

UndervaluedFair: $12.64Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

SHC1 strengths · Avg: 10.0/10
Operating MarginProfitability
35.7%10/10

Strong operational efficiency at 35.7%

Areas to Watch

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

SHC4 concerns · Avg: 3.8/10
PEG RatioValuation
1.684/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

EPS GrowthGrowth
1.8%4/10

1.8% earnings growth

Profit MarginProfitability
6.7%3/10

6.7% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : SHC

The strongest argument for SHC centers on Operating Margin.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Bear Case : SHC

The primary concerns for SHC are PEG Ratio, Revenue Growth, EPS Growth. A P/E of 51.2x leaves little room for execution misses. Debt-to-equity of 4.14 is elevated, increasing financial risk.

Key Dynamics to Monitor

SHC carries more volatility with a beta of 1.88 — expect wider price swings.

IQV is growing revenue faster at 10.3% — sustainability is the question.

IQV generates stronger free cash flow (561M), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IQV scores higher overall (72/100 vs 62/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Sotera Health Co

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.

Want to dig deeper into these stocks?